Addex to present at the 2025 swiss equities baader conference

Geneva, switzerland, january 8, 2025 - addex therapeutics (six/nasdaq: adxn), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that dr robert lÜtjens, head of discovery - biology, will present at the swiss equities baader conference being held in bad ragaz, switzerland, january 08-10, 2025.
ADXN Ratings Summary
ADXN Quant Ranking